Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more
Shanghai Kaibao Pharmaceutical - Asset Resilience Ratio
Shanghai Kaibao Pharmaceutical (300039) has an Asset Resilience Ratio of 17.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Shanghai Kaibao Pharmaceutical's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Kaibao Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥860.80 Million | 17.36% |
| Total Liquid Assets | CN¥860.80 Million | 17.36% |
Asset Resilience Insights
- Good Liquidity Position: Shanghai Kaibao Pharmaceutical maintains a healthy 17.36% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Kaibao Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Shanghai Kaibao Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Shanghai Kaibao Pharmaceutical (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Kaibao Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.98% | CN¥180.02 Million | CN¥4.52 Billion | +0.71pp |
| 2023-12-31 | 3.28% | CN¥150.01 Million | CN¥4.58 Billion | +0.08pp |
| 2022-12-31 | 3.19% | CN¥136.07 Million | CN¥4.26 Billion | +1.67pp |
| 2021-12-31 | 1.53% | CN¥51.26 Million | CN¥3.36 Billion | -2.46pp |
| 2020-12-31 | 3.98% | CN¥114.65 Million | CN¥2.88 Billion | -13.10pp |
| 2019-12-31 | 17.08% | CN¥485.57 Million | CN¥2.84 Billion | +14.01pp |
| 2018-12-31 | 3.07% | CN¥84.28 Million | CN¥2.75 Billion | -0.79pp |
| 2017-12-31 | 3.86% | CN¥103.38 Million | CN¥2.68 Billion | +2.21pp |
| 2016-12-31 | 1.64% | CN¥41.58 Million | CN¥2.53 Billion | +0.67pp |
| 2015-12-31 | 0.98% | CN¥23.72 Million | CN¥2.43 Billion | -8.00pp |
| 2014-12-31 | 8.97% | CN¥190.00 Million | CN¥2.12 Billion | -- |